Collaboration

The Center for Regenerative Biotherapeutics works with industry and academia to expand its ability to touch patients' lives, bring patients hope and solve some of medicine’s greatest challenges. The center works with collaborators in industry to develop and optimize new and unique therapeutics in late-stage discovery. It facilitates connections with global leaders to design early-stage clinical trials and manufacture products for these trials. Collaborations focus on finding solutions for people with unique needs for hope and healing: patients with cancer or autoimmune conditions and patients needing transplants.

Partnerships allow Mayo Clinic to provide clinical and manufacturing know-how for clinical translation. Mayo's internal manufacturing capabilities provide a unique ability to codevelop products with biotech companies that have promising early-stage technologies. The Center for Regenerative Biotherapeutics helps to bridge cost and cGMP knowledge barriers and bring potential cures to patients faster.

The center works with external collaborators to scale impact for patients. We work with Mayo Clinic experts to translate discoveries to therapies for first-in-human clinical trials. Once products are established, we connect with industry partners to license Mayo Clinic products for early-phase clinical trials.

The center also works to bring external discoveries into Mayo Clinic to accelerate their optimization and translation to patients. We combine our partners' technical knowledge with our unparalleled clinical expertise and industry-caliber manufacturing capabilities to bring patients truly novel and cutting-edge treatments and cures.

Regenerative Medicine Minnesota

Mayo Clinic is a partner in Regenerative Medicine Minnesota, a collaborative effort to advance regenerative medicine and position Minnesota at the forefront of this field. This statewide initiative aims to improve the health of Minnesotans by advancing regenerative medicine and opening new economic opportunities through the commercialization of technologies. In May 2014, the Minnesota Legislature allocated $4.5 million for the first year and $4.35 million a year thereafter to fund research and biobusiness development initiatives that improve or increase access to regenerative medicine throughout the state.

Mayo Clinic researchers have been awarded grants to support innovative research, drive regenerative medicine biobusiness and biotechnology, and develop outreach education programs to further the field of regenerative medicine.

Learn more on the Regenerative Medicine Minnesota website.